Scientists discover genetic switch controlling heart elasticity through RBM20 protein variants

The human heart is an organ built for constant negotiation. Every beat demands that muscle fibers stretch and recoil, flex and hold, responding to the body's shifting needs without pause or complaint. This elasticity—the heart's ability to give and spring back—depends on a molecular choreography so intricate that a single misplaced step can unravel it entirely. At the center of that choreography sits a protein called RBM20, which acts as a kind of editor, deciding which instructions get read and which get skipped when heart cells manufacture the proteins they need to survive.

RBM20's most important job is managing titin, a protein so large it functions like a biological spring, giving heart muscle its characteristic flexibility. When RBM20 goes wrong—when it mutates or misfires—the heart loses that elasticity. The muscle stiffens. Blood cannot flow as it should. Cardiomyopathy and heart failure follow. For years, researchers understood RBM20 as a single switch: either it worked or it didn't. Either the heart had enough of it or it didn't. But a team led by Dr. Michael Gotthardt at the Max Delbrück Center in Berlin discovered something far more subtle. The RBM20 gene, they found, does not flip on from a single starting point. It flips on from multiple starting points, each one producing a slightly different version of the protein.

The discovery came almost by accident. The researchers engineered mice with a genetic modification designed to block RBM20 production entirely. They inserted a reporter gene—a kind of genetic tracer—at what they believed was the sole starting point for RBM20 transcription. The mice should have stopped making the protein. Instead, they kept making it, just in a shorter form. "That completely surprised us," recalls Dr. Michael Radke, one of the paper's lead authors. The team then expanded their investigation, using RNA sequencing and molecular imaging to examine heart tissue from mice, rats, and human patients. What emerged was a picture of unexpected complexity: the RBM20 gene relies on multiple transcription start sites, not one. The cell can choose where to begin reading the genetic instructions, and that choice matters.

The balance between these different RBM20 isoforms—these distinct protein variants—shifts dramatically around birth, when a heart transitions from supporting fetal life to independent adult function. More striking still, the researchers found disease-specific patterns in human heart tissue. In hypertrophic cardiomyopathy, where the heart muscle thickens abnormally, the total amount of RBM20 was elevated in diseased samples compared to healthy controls, but that increase came almost entirely from the shorter isoform. In dilated cardiomyopathy, where the heart weakens and enlarges, both isoforms were elevated, with a stronger rise in the longer form. The same protein, produced in different proportions, correlated with different diseases.

This distinction opens a new therapeutic door. RBM20 has already attracted attention from drug developers because manipulating its activity can restore heart-muscle flexibility. But if the protein comes in multiple forms, and if those forms behave differently in disease, then future treatments might not simply increase or decrease RBM20 overall. Instead, they could selectively shift the balance between isoforms—nudging the heart toward producing more of one form and less of another. "Selectively shifting the balance between the two forms could eventually help researchers develop more precise ways to adjust heart-muscle stiffness, while reducing unwanted effects," Gotthardt explained. The implication is significant: therapies could become more targeted, more nuanced, potentially causing fewer side effects than blunt interventions that simply turn a protein up or down.

The work, published in Nature Communications, represents a fundamental shift in how scientists think about RBM20's role in cardiac disease. For decades, the focus was on quantity—how much protein the heart was making. Now the question becomes which version. Radke notes that this complexity suggests future therapeutic strategies will need to account for isoform composition, not just total protein levels. The next phase of research will test these isoforms in larger patient populations and animal disease models, working to understand exactly what each variant does and how to manipulate their production safely. The heart's elasticity, it turns out, depends on choices made at the genetic level—and those choices may soon become targets for a new generation of heart medicines.